Gefitinib, a classic epidermal growth factor receptor (EGFR) tyrosine kinase receptor inhibitor, has been a bottleneck in the treatment of NSCLC due to the problem of drug resistance (Onitsuka et al., 2010; Sun et al., 2020). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.